CellSight Technologies Inc.

CellSight Technologies is a privately held molecular imaging company. Our mission is to discover, develop and commercialize PET (Positron Emission Tomography) imaging companion diagnostics for the development of therapies and the clinical management of patients. CellSight was recently granted eIND approval for a novel probe to visualize activated T cells. [18F]F-AraG is a substrate for enzymes naturally over-expressed inside activated T cells which allows us to image the level of expression in living subjects with no alteration of the T cells. Imagine being able to provide an immuno-oncology patient with efficacy information within days versus the months required with current practices. CellSight also has eIND approval on a reporter gene / PET probe combination that allows repeated imaging or engineered cells. The GSV1-tk reporter gene in conjunction with the [18F]FHBG PET probe has been used clinically to monitor therapeutic cell migration, proliferation and survival. I invite you to visit our website for additional information: www.cellsighttech.com